vs
晨星（MORN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是晨星的1.2倍（$772.1M vs $641.1M），晨星净利率更高（18.0% vs 12.7%，领先5.2%），晨星同比增速更快（8.5% vs 5.9%），Revvity自由现金流更多（$161.8M vs $161.3M），过去两年Revvity的营收复合增速更高（9.0% vs 8.7%）
晨星（Morningstar, Inc.）是总部位于美国伊利诺伊州芝加哥的金融服务机构，由乔·曼苏托于1984年创立，面向全球提供全方位的投资研究、投资管理等专业服务，是全球颇具知名度的投资资讯服务提供商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MORN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$641.1M
营收增速更快
MORN
高出2.6%
5.9%
净利率更高
MORN
高出5.2%
12.7%
自由现金流更多
RVTY
多$489.0K
$161.3M
两年增速更快
RVTY
近两年复合增速
8.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $641.1M | $772.1M |
| 净利润 | $115.1M | $98.4M |
| 毛利率 | 61.1% | — |
| 营业利润率 | 24.9% | 14.5% |
| 净利率 | 18.0% | 12.7% |
| 营收同比 | 8.5% | 5.9% |
| 净利润同比 | -1.5% | 3.9% |
| 每股收益（稀释后） | $2.79 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MORNRVTY
| Q4 25 | $641.1M | $772.1M | ||
| Q3 25 | $617.4M | $698.9M | ||
| Q2 25 | $605.1M | $720.3M | ||
| Q1 25 | $581.9M | $664.8M | ||
| Q4 24 | $591.0M | $729.4M | ||
| Q3 24 | $569.4M | $684.0M | ||
| Q2 24 | $571.9M | $691.7M | ||
| Q1 24 | $542.8M | $649.9M |
净利润MORNRVTY
| Q4 25 | $115.1M | $98.4M | ||
| Q3 25 | $91.6M | $46.7M | ||
| Q2 25 | $89.0M | $53.9M | ||
| Q1 25 | $78.5M | $42.2M | ||
| Q4 24 | $116.9M | $94.6M | ||
| Q3 24 | $119.7M | $94.4M | ||
| Q2 24 | $69.1M | $55.4M | ||
| Q1 24 | $64.2M | $26.0M |
毛利率MORNRVTY
| Q4 25 | 61.1% | — | ||
| Q3 25 | 60.9% | 53.6% | ||
| Q2 25 | 61.9% | 54.5% | ||
| Q1 25 | 60.2% | 56.5% | ||
| Q4 24 | 60.7% | — | ||
| Q3 24 | 60.9% | 56.3% | ||
| Q2 24 | 61.1% | 55.7% | ||
| Q1 24 | 59.8% | 54.6% |
营业利润率MORNRVTY
| Q4 25 | 24.9% | 14.5% | ||
| Q3 25 | 20.7% | 11.7% | ||
| Q2 25 | 20.7% | 12.6% | ||
| Q1 25 | 19.6% | 10.9% | ||
| Q4 24 | 28.5% | 16.3% | ||
| Q3 24 | 20.3% | 14.3% | ||
| Q2 24 | 19.0% | 12.4% | ||
| Q1 24 | 17.1% | 6.8% |
净利率MORNRVTY
| Q4 25 | 18.0% | 12.7% | ||
| Q3 25 | 14.8% | 6.7% | ||
| Q2 25 | 14.7% | 7.5% | ||
| Q1 25 | 13.5% | 6.4% | ||
| Q4 24 | 19.8% | 13.0% | ||
| Q3 24 | 21.0% | 13.8% | ||
| Q2 24 | 12.1% | 8.0% | ||
| Q1 24 | 11.8% | 4.0% |
每股收益（稀释后）MORNRVTY
| Q4 25 | $2.79 | $0.86 | ||
| Q3 25 | $2.17 | $0.40 | ||
| Q2 25 | $2.09 | $0.46 | ||
| Q1 25 | $1.82 | $0.35 | ||
| Q4 24 | $2.72 | $0.77 | ||
| Q3 24 | $2.77 | $0.77 | ||
| Q2 24 | $1.60 | $0.45 | ||
| Q1 24 | $1.49 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $528.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $3.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MORNRVTY
| Q4 25 | $528.7M | $919.9M | ||
| Q3 25 | $40.3M | $931.4M | ||
| Q2 25 | $38.1M | $991.8M | ||
| Q1 25 | $47.7M | $1.1B | ||
| Q4 24 | $551.0M | $1.2B | ||
| Q3 24 | $48.8M | $1.2B | ||
| Q2 24 | $48.0M | $2.0B | ||
| Q1 24 | $55.4M | $1.7B |
总债务MORNRVTY
| Q4 25 | — | — | ||
| Q3 25 | $848.9M | — | ||
| Q2 25 | $838.8M | — | ||
| Q1 25 | $803.7M | — | ||
| Q4 24 | $698.6M | — | ||
| Q3 24 | $864.7M | — | ||
| Q2 24 | $899.6M | — | ||
| Q1 24 | $917.3M | — |
股东权益MORNRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产MORNRVTY
| Q4 25 | $3.6B | $12.2B | ||
| Q3 25 | $3.6B | $12.1B | ||
| Q2 25 | $3.6B | $12.4B | ||
| Q1 25 | $3.6B | $12.4B | ||
| Q4 24 | $3.5B | $12.4B | ||
| Q3 24 | $3.6B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
负债/权益比MORNRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.56× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $204.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $161.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.2% | 21.0% |
| 资本支出强度资本支出/营收 | 6.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $442.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MORNRVTY
| Q4 25 | $204.0M | $182.0M | ||
| Q3 25 | $195.7M | $138.5M | ||
| Q2 25 | $99.0M | $134.3M | ||
| Q1 25 | $91.0M | $128.2M | ||
| Q4 24 | $153.4M | $174.2M | ||
| Q3 24 | $191.9M | $147.9M | ||
| Q2 24 | $152.7M | $158.6M | ||
| Q1 24 | $93.6M | $147.6M |
自由现金流MORNRVTY
| Q4 25 | $161.3M | $161.8M | ||
| Q3 25 | $160.1M | $120.0M | ||
| Q2 25 | $62.4M | $115.5M | ||
| Q1 25 | $58.8M | $112.2M | ||
| Q4 24 | $112.8M | $149.8M | ||
| Q3 24 | $155.8M | $125.6M | ||
| Q2 24 | $120.8M | $136.6M | ||
| Q1 24 | $59.5M | $129.7M |
自由现金流率MORNRVTY
| Q4 25 | 25.2% | 21.0% | ||
| Q3 25 | 25.9% | 17.2% | ||
| Q2 25 | 10.3% | 16.0% | ||
| Q1 25 | 10.1% | 16.9% | ||
| Q4 24 | 19.1% | 20.5% | ||
| Q3 24 | 27.4% | 18.4% | ||
| Q2 24 | 21.1% | 19.7% | ||
| Q1 24 | 11.0% | 20.0% |
资本支出强度MORNRVTY
| Q4 25 | 6.7% | 2.6% | ||
| Q3 25 | 5.8% | 2.6% | ||
| Q2 25 | 6.0% | 2.6% | ||
| Q1 25 | 5.5% | 2.4% | ||
| Q4 24 | 6.9% | 3.4% | ||
| Q3 24 | 6.3% | 3.3% | ||
| Q2 24 | 5.6% | 3.2% | ||
| Q1 24 | 6.3% | 2.7% |
现金转化率MORNRVTY
| Q4 25 | 1.77× | 1.85× | ||
| Q3 25 | 2.14× | 2.97× | ||
| Q2 25 | 1.11× | 2.49× | ||
| Q1 25 | 1.16× | 3.03× | ||
| Q4 24 | 1.31× | 1.84× | ||
| Q3 24 | 1.60× | 1.57× | ||
| Q2 24 | 2.21× | 2.87× | ||
| Q1 24 | 1.46× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MORN
| Pitch Book Segment | $172.6M | 27% |
| Morningstar Credit Segment | $166.7M | 26% |
| Transaction Based | $113.1M | 18% |
| Asset Based | $90.2M | 14% |
| Morningstar Retirement Segment | $38.1M | 6% |
| Morningstar Sustainalytics | $27.8M | 4% |
| Morningstar Indexes | $22.5M | 4% |
| Morningstar Wealth Segment | $2.3M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
